Form 8-K - Current report:
SEC Accession No. 0001764013-25-000121
Filing Date
2025-07-29
Accepted
2025-07-29 16:57:27
Documents
12
Period of Report
2025-07-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K imvt-20250728.htm   iXBRL 8-K 32523
  Complete submission text file 0001764013-25-000121.txt   149786

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imvt-20250728.xsd EX-101.SCH 1779
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imvt-20250728_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imvt-20250728_pre.xml EX-101.PRE 12506
14 EXTRACTED XBRL INSTANCE DOCUMENT imvt-20250728_htm.xml XML 2712
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 251162635
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)